Pharmacyte Biotech, Inc. (PHCY) - 10-Q Summary
Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2017
Business Overview: A clinical-stage biotechnology company developing treatments for cancer (specifically pancreas cancer) and diabetes using proprietary "Cell-in-a-Box" live cell encapsulation technology. The company is also exploring cannabinoid-based therapies. As of January 31, 2017, the company had no commercial revenue.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2017 | Nine Months Ended Jan 31, 2017 | Balance Sheet (Jan 31, 2017) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,282,146) | $(3,288,663) | N/A |
| Operating Expenses | $1,282,015 | $3,287,607 | N/A |
| Cash and Equivalents | N/A | N/A | $2,464,271 |
| Total Assets | N/A | N/A | $7,614,943 |
| Total Liabilities | N/A | N/A | $578,267 |
| Working Capital | N/A | N/A | $1,907,684 |
| Accumulated Deficit | N/A | N/A | $(87,980,280) |
Cash Flow (Nine Months Ended Jan 31, 2017):
- Net cash used in operating activities: $(2,538,575)
- Net cash provided by financing activities: $3,080,883 (primarily from sale of common stock)
- Net increase in cash: $543,446
Material Changes vs. Prior Period
- Operating Expenses: Decreased by $510,136 for the three months and $1,654,676 for the nine months compared to the prior year periods. The reduction was driven primarily by lower general and administrative expenses (consulting fees) and compensation expenses, partially offset by slight increases in R&D costs.
- Net Loss: Improved (decreased) from $(1,791,097) to $(1,282,146) for the three months, and from $(4,941,720) to $(3,288,663) for the nine months.
- Liquidity: Cash increased from $1,920,825 (April 30, 2016) to $2,464,271 (January 31, 2017), funded by equity raises.
- License Obligations: The $150,000 license agreement obligation recorded as of April 30, 2016, was paid in full by January 31, 2017.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management believes current cash and the ability to raise capital via its S-3 Registration Statement (at-the-market offerings) will fund operations through January 31, 2018. Continued access to capital is critical for clinical trials.
- Clinical Development: A Pre-IND meeting with the FDA was held on January 17, 2017, regarding a clinical trial for locally advanced, inoperable non-metastatic pancreas cancer. Approval of the Investigational New Drug (IND) application is required to commence trials.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of January 31, 2017, due to material weaknesses including ineffective corporate governance, insufficient segregation of duties, and inadequate IT controls.
- Risk Factors: Significant risks include the failure to obtain FDA approval for the IND, inability to raise additional capital, and the inherent risks of clinical-stage biotechnology development.
- Subsequent Events: In March 2017, the company appointed a new CFO and amended executive compensation agreements, granting significant stock and options to the CEO, COO, and new CFO.
Investor Verification Checklist
- Funding Runway: Verify the company's ability to raise capital through its S-3 registration statement to sustain operations beyond January 2018.
- FDA Status: Monitor the status of the Investigational New Drug (IND) application for the pancreas cancer therapy following the January 2017 Pre-IND meeting.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Dilution Risk: Review the impact of recent and planned equity issuances (stock sales and executive option grants) on existing shareholder ownership.
- Related Party Transactions: Scrutinize ongoing payments and milestone obligations to related parties (e.g., SG Austria, Austrianova) which represent significant future contingent liabilities.